EyePoint announced the launch of Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The product was approved by the Food and Drug Administration (FDA) in October 2018. 

Yutiq is a sterile non-bioerodible intravitreal implant containing fluocinolone acetonide 0.18mg in a 36-month sustained-release drug delivery system. It is designed to release fluocinolone acetonide, a corticosteroid, at an initial rate of 0.25mcg/day.

Yutiq is supplied as a 0.18mg single-dose, preloaded applicator with a 25-gauge needle for ophthalmic intravitreal injection administered in the physician’s office. Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection. Following the injection, patients should be monitored for change in intraocular pressure and for endophthalmitis.

Related Articles

“Yutiq is the first FDA-approved fluocinolone acetonide micro-insert to address this serious condition that is the third leading cause of blindness in the country,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “One micro-insert of Yutiq has the ability to deliver up to 3 years of fluocinolone acetonide, a commonly used steroid, with continuous dosing that avoids the peaks and valleys of local corticosteroids, the current standard of care.”

follow @RheumAdvisor

For more information call (888) 812-6198 or visit Yutiq.com.

This article originally appeared on MPR